RT Journal Article
SR Electronic
T1 Alterations of the Retinoblastoma and P16 Pathway Correlate with Promoter Methylation in Malignant Fibrous Histiocytomas
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3461
OP 3465
VO 26
IS 5A
A1 BRINCK, ULRICH
A1 SCHLOTT, THILO
A1 STÖRBER, STEFFI
A1 STACHURA, JERZY
A1 BORTKIEWICZ, PAWEL
A1 NAGEL, WOLF-DIETER
A1 HASSE, FRANK MICHAEL
A1 CORDON-CARDO, CARLOS
A1 FISCHER, GÖSTA
A1 KORABIOWSKA, MONIKA
YR 2006
UL http://ar.iiarjournals.org/content/26/5A/3461.abstract
AB Recent reports indicate that the alterations in the p16 and pRb pathways can influence tumour progression and poor prognosis in several tumours. The objective of this study was to analyse p16 and pRb expression in161 patients with malignant fibrous histiocytomas (MFH). By immunohistochemistry, p16 and pRb were demonstrated in 25% and 56% of MFH, respectively. Cox regression analysis demonstrated an independent prognostic influence of both genes. Generally, the loss of p16 and pRb expression correlated with poorer prognosis. Promoter methylation of p16 was found in 16/42 of p16 negative MFH and of pRb in 2/42 of pRb-negative MFH. It can be concluded that p16 and pRb alterations play an important role in the progression of soft tissue sarcomas. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved